Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
Ascentage Pharma announced that lisaftoclax has been included in China's 2026 National Reimbursement Drug List (NRDL) for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, while olverembatinib successfully renewed its NRDL coverage for chronic myeloid leukemia treatment. Both approvals take effect January 1, 2027, and represent all approved indications for both drugs now being covered by the NRDL, significantly improving patient access and affordability in China.